Concord Biotech Limited — PPTs, 13-11-2025: Investor Presentation

Concord Biotech reported Q2 FY26 revenue of Rs 247 Cr (down 20% YoY) and H1 FY26 revenue of Rs 451 Cr (down 14% YoY), with PAT at Rs 63 Cr and Rs 107 Cr respectively. This revenue dip was mainly due to temporary sales postponements from regulatory delays for EU supply, US customer order holds, and a Middle East tender deferment. Despite this, gross profit margins remained strong at 80.2% for Q2, reflecting solid unit economics, with API and domestic segments being key revenue drivers.

Recent highlights include successful regulatory inspections (US FDA, EU GMP, NAFDAC) across multiple facilities, bolstering global market access. The company is in advanced discussions for API supplies with innovator companies, increasing second-source qualifications, and noted an uptick in injectables revenue. Two pipeline products are expected to commercialize in six months, and an investment marks an entry into Cell & Gene Therapy.

Management views the revenue decline as a temporary timing issue, expecting recovery in future quarters. The strategic focus is on geographic expansion, deepening client relationships, and broadening its product portfolio (API & formulations) while investing in innovation to drive sustainable, long-term growth.